Global resolution of patent issues between Sandoz and AbbVie relating to Hyrimoz (adalimumab biosimilar).
Sandoz has announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz (adalimumab) for reference medicine Humira (adalimumab). Under the terms of the agreement, AbbVie grants Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira, beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on October 16, 2018 in most countries in the European Union, and on other dates in various other countries outside the US where AbbVie has IP.
In the US, the license period will begin on September 30, 2023.
Sandoz will pay royalties to AbbVie for licensing its Humira patents. All litigation pending between the parties will be dismissed. AbbVie will make no payments to Sandoz. The precise terms are confidential between the parties.
Comment: Hyrimoz was EU approved on 27 July 2018 and the FDA accepted the drug for filing on 16 January 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins